文献速递肿瘤 PET/CT

霍奇金淋巴瘤与弥漫大B细胞淋巴瘤治疗后疗效评估的PET/CT

PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma.
PubMed 文献 · Semin Nucl Med · 2017-09-19

本文综述了FDG-PET在霍奇金淋巴瘤和弥漫大B细胞淋巴瘤治疗后疗效评估中的作用。FDG-PET阴性预测值很高,PET阴性患者可在有效化疗后安全省略放疗;但早期和中期霍奇金淋巴瘤中依据治疗结束PET放弃放疗的可靠性尚待大型临床试验证实。自2007年起治疗结束FDG-PET已纳入国际工作组标准,推荐的五分法成为PET疗效评估的标准。

要点

  • FDG-PET在化疗后阴性预测值很高,PET阴性晚期霍奇金淋巴瘤患者可在有效化疗后安全省略放疗。
  • 弥漫大B细胞淋巴瘤诱导治疗后FDG-PET预测价值高于单独CT,可提供解剖影像无法获得的预后信息。
  • 推荐的五分法已成为PET疗效评估标准,但PET扫描的后续处理可能受前序和后续治疗影响。

核心结论

  • FDG-PET在淋巴瘤疗效评估中具有高预测价值,治疗结束PET已纳入国际工作组标准并成为侵袭性淋巴瘤疗效评估的首选影像工具。
  • PET阴性霍奇金淋巴瘤患者可在有效化疗后安全省略放疗,但早期和中期霍奇金淋巴瘤中依据治疗结束PET放弃放疗的可靠性尚待大型临床试验证实。
  • 侵袭性非霍奇金淋巴瘤的降阶梯策略试验结果提示,标准化学免疫治疗后FDG-PET阴性者可安全省略放疗。

研究设计与样本

  • 综述,总结了FDG-PET用于霍奇金淋巴瘤和弥漫大B细胞淋巴瘤分期、再分期及疗效评估的文献与临床试验结果。

主要发现

  • FDG-PET在化疗后具有很高的阴性预测值,PET阴性晚期霍奇金淋巴瘤患者在接受博来霉素、依托泊苷、多柔比星、环磷酰胺、长春新碱、丙卡巴肼和泼尼松等方案有效化疗后可安全省略放疗。
  • 弥漫大B细胞淋巴瘤诱导治疗后FDG-PET的预测价值高于单独CT,可提供解剖影像无法获得的预后信息。
  • 侵袭性非霍奇金淋巴瘤降阶梯策略试验的近期结果提示,标准化学免疫治疗后FDG-PET阴性者可安全省略放疗。

关键数值与推荐

  • 自2007年起,治疗结束FDG-PET被纳入国际工作组标准,成为侵袭性淋巴瘤疗效评估的首选影像工具。
  • 推荐的五分法已成为PET疗效评估的标准,但PET扫描的后续处理可能受前序和后续治疗影响。

临床怎么用

  • PET阴性晚期霍奇金淋巴瘤患者可在有效化疗后安全省略放疗。
  • 侵袭性非霍奇金淋巴瘤降阶梯策略试验结果提示,标准化学免疫治疗后FDG-PET阴性者可安全省略放疗(作者基于试验结果的提示)。

局限性

  • 早期和中期霍奇金淋巴瘤中依据治疗结束PET放弃放疗的可靠性尚待大型临床试验证实。
  • PET扫描的后续处理可能受前序和后续治疗影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the course of many decades, combined chemotherapy and radiotherapy adapted to the stage of disease have become the optimal and standard treatment for Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma. Besides achieving optimized cure rates of the underlying disease, reduction of toxicity has become a major goal. Since the introduction of FDG-PET for the staging and restaging of patients with lymphoma, a high predictive value of F-18-FDG-PET in response assessment has been observed. Several PET-response-guided therapy regimens have already been established, and even more PET-adapted study designs are being tested in large study groups. PET has a very high negative predictive value following chemotherapy, and radiotherapy can be safely omitted in PET-negative patients with HL after effective chemotherapy with regimens such as bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in advanced stages. As "state-of-the-art" PET-guided therapy is based on the results of large clinical trials, the reliability of end-of-treatment PET as a basis for abandoning radiotherapy in early and intermediate HL stages remains to be shown. As in HL, the predictive value of FDG-PET after induction therapy of diffuse large B-cell lymphoma is higher than that of CT alone so that we obtain relevant prognostic information unavailable through anatomical imaging. Recent results from trials in aggressive non-HL with a de-escalating strategy suggest that radiotherapy may be safely omitted if FDG-PET is negative after standard chemoimmunotherapy. Since 2007, FDG-PET at end of treatment is integrated into the International Working Group criteria and became the imaging tool of choice for response assessment in aggressive lymphoma. Robust and reproducible interpretation criteria are being used both in the ongoing clinical trials and in daily routine. The recommended five-point scale has become the standard in PET response assessment, with the caveat that the consequence of a PET scan may be influenced by foregoing and following treatments.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kobe C, Dietlein M, Hellwig D, et al. PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma. Semin Nucl Med. 2017. PMID: 29195615. doi:10.1053/j.semnuclmed.2017.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。